UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2283-3
Program Prior Authorization/Medical Necessity
Medication Epsolay® (benzoyl peroxide)*
P&T Approval Date 8/2022, 8/2023, 8/2024
Effective Date 11/1/2024
1. Background:
Epsolay (benzoyl peroxide)* topical cream is indicated for the treatment of inflammatory
lesions of rosacea in adults.
2. Coverage Criteriaa:
A. Initial Authorization
1. Epsolay* will be approved based on all of the following criteria:
a. Diagnosis of rosacea
-AND-
b. Treatment of inflammatory lesions
-AND-
c. History of failure (after a 30 day-trial), contraindication or intolerance to two of the
following:
1) topical metronidazole cream or gel (generic Metrocream, Metrogel)
2) Finacea (azelaic acid 15%)
3) Soolantra (ivermectin 1% cream)
Authorization will be issued for 6 months.
B. Reauthorization
1. Epsolay* will be approved based on the following criterion:
a. Documentation of positive clinical response to therapy demonstrated by a reduction
in inflammatory lesion counts
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2024 UnitedHealthcare Services, Inc.
1
*Epsolay is typically excluded from coverage
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
4. References:
1. Epsolay [package insert]. Fort Worth, TX: Galderma Laboratories, L.P. April 2023.
2. Thiboutot D, Anderson R, Cook-Bolden F, Draelos Z, Gallo RL, Granstein RD, Kang S, Macsai
M, Gold LS, Tan J. Standard management options for rosacea: The 2019 update by the National
Rosacea Society Expert Committee. J Am Acad Dermatol. 2020;82(6):1501-1510.
Program Prior Authorization/Medical Necessity - Epsolay
Change Control
8/2022 New program.
8/2023 Added that Epsolay typically excluded. Included brand Finacea as trial
option. Updated references.
8/2024 Annual review. Removed that step therapy may be in place.
© 2024 UnitedHealthcare Services, Inc.
2